Cerenome is trading 5% down at $2.56 as insurance-coverage concerns weigh on healthcare stocks; no new company-specific announcement was identified for September 9, 2026.
- Latest company updates were its August 20 conference presentation and August 14 second-quarter results.
- Those results reported a larger-than-expected loss and revenue miss.
- Broader risk-off sentiment and geopolitical tensions are additional headwinds.